Paper Details

  1. Home
  2. Paper Details

A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder.

Author: FeighnerJ P, HendricksonG A, MeridethC H

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.

Overview

Buspirone (16.5 mg/day) was comparable to diazepam (15 mg/day) in relieving anxiety and depression symptoms. Buspirone showed greater improvement in impaired cognition and confusion compared to diazepam, with fewer and less severe side effects, such as sedation and drowsiness.
Paper Details　
Original Abstract of the Article :
The safety and antianxiety and antidepressive effects of buspirone (average 16.5 mg/day) were compared in a double-blind trial with those of diazepam (15 mg/day). The two drugs were nearly equivalent in relieving symptoms of both anxiety and depression in 100 patients. Scores on the impaired cogniti...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/6130066

データ提供：米国国立医学図書館（NLM）

A Double-Blind Comparison of Buspirone and Diazepam in Generalized Anxiety Disorder

Generalized anxiety disorder (GAD), a common mental health condition characterized by persistent worry and anxiety, can be challenging to manage. This study explores the world of psychopharmacology, comparing the efficacy and safety of two medications, buspirone and diazepam, in treating GAD. The research employs a double-blind trial, evaluating the effectiveness of these medications in relieving anxiety and depression, much like carefully comparing two trails in a desert landscape, seeking the path that leads to the most favorable outcome.

Buspirone: A Promising Option for GAD Treatment

The study found that buspirone was nearly equivalent to diazepam in relieving symptoms of anxiety and depression, with significantly fewer side effects like sedation and drowsiness. These findings suggest that buspirone may be a valuable alternative for patients with GAD, especially those experiencing associated depression. It's like finding a smoother path through a desert, offering a more comfortable and efficient journey to well-being.

Navigating GAD Treatment with Buspirone

This study highlights the importance of considering alternative treatment options for GAD, particularly for patients who may be sensitive to the sedative effects of traditional benzodiazepines like diazepam. It encourages further research into the efficacy and safety of buspirone in managing GAD, exploring its potential as a preferred treatment option for certain patients, much like finding a hidden oasis with unique and valuable resources.

Dr. Camel's Conclusion

This research provides valuable insights into the comparative efficacy and safety of buspirone and diazepam in treating GAD. It underscores the importance of individualizing treatment approaches, carefully considering patient needs and potential side effects. It's a reminder that the desert landscape of mental health treatment offers a variety of pathways, and finding the right path for each patient is crucial for successful management of this complex condition.

Date :
  1. Date Completed 1983-03-24
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

6130066

DOI: Digital Object Identifier

6130066

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.